RMC-5552

mTORC1-selective bi-steric mTOR inhibitor

QW IP activity in xeno., 5552 in Ph. I for cancer

from linking of ÒrapalogÓ + mTOR inh. + opt

Nature Chemical Biology

Revolution Medicines, Redwood City, US

3. The Revolution Medicines selective mTORC1 complex inhibitor, RMC-4529, is a Òbi-stericÓ inhibitor that has a rapamycin-derived, FKBP12-recruiting allosteric mTOR inhibitor covalently linked to an active-site (orthosteric) inhibitor of…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.